Latest Breaking News On - Medical genetics service - Page 1 : comparemela.com

Azafaros Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

Azafaros Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesRoberto giuglianiPorto alegreDrug administrationGenetics serviceLeiden universityEuropean medicines agencyHealthcare products regulatory agencyMedical genetics serviceHospital clinicas de porto alegreLead principal investigatorDaniel almeidaStefano portolanoRare pediatric disease designationsUnited states food

Azafaros Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolledTopline data from the study, exp.

United kingdomUnited statesPorto alegreRoberto giuglianiLeiden universityEuropean medicines agencyDrug administrationHealthcare products regulatory agencyGenetics serviceAzafaro phaseMedical genetics serviceHospital clinicas de porto alegreLead principal investigatorDaniel almeidaStefano portolanoRare pediatric disease designations

Regenxbio (RGNX) Reports Positive Interim Data from Phase I/II/III CAMPSIITE Trial of RGX-121

Regenxbio (RGNX) Reports Positive Interim Data from Phase I/II/III CAMPSIITE Trial of RGX-121
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Porto alegreRoberto giuglianiSteve pakolaGenetics serviceDepartment of geneticsMucopolysaccharidosis typeInborn errorsChief medical officerMedical genetics service

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium,.

United statesRoberto giuglianiPorto alegreDana cormackRaymond wangChris brinzeyUniversity of californiaTechnology platformTechnology platform licenseesDivision of metabolic disordersProgram for the study of neurodevelopmentGenetics serviceCorporate communicationsDepartment of pediatricsDepartment of geneticsInborn errors

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking.

United statesSteven foltzApril gilesRoberto giuglianiBrad hollidgeSamantha yostAmanda zhangSunjung kimRandy qianJustin glennRaymond wangWei hua leeSubha karumuthil melethilChris brinzeyNina hunterJared smith